Mark Krailo

30.7k total citations · 4 hit papers
392 papers, 18.7k citations indexed

About

Mark Krailo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Neurology. According to data from OpenAlex, Mark Krailo has authored 392 papers receiving a total of 18.7k indexed citations (citations by other indexed papers that have themselves been cited), including 143 papers in Pulmonary and Respiratory Medicine, 129 papers in Oncology and 106 papers in Neurology. Recurrent topics in Mark Krailo's work include Sarcoma Diagnosis and Treatment (106 papers), Neuroblastoma Research and Treatments (101 papers) and Testicular diseases and treatments (71 papers). Mark Krailo is often cited by papers focused on Sarcoma Diagnosis and Treatment (106 papers), Neuroblastoma Research and Treatments (101 papers) and Testicular diseases and treatments (71 papers). Mark Krailo collaborates with scholars based in United States, Canada and Switzerland. Mark Krailo's co-authors include Gregory H. Reaman, Holcombe E. Grier, Susan M. Blaney, Malcolm C. Pike, Mark L. Bernstein, Paul A. Meyers, Brian E. Henderson, Peter C. Adamson, Richard B. Womer and Zhengjia Chen and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

Mark Krailo

390 papers receiving 18.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone

2003 948 citations Holcombe E. Grier, Mark Krailo et al. profile →
‘Hormonal’ risk factors, ‘breast tissue age’ and the age-incidence of breast cancer

1983 520 citations Mark Krailo et al. profile →
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

2008 520 citations Paul A. Meyers, Cindy L. Schwartz et al. Journal of Clinical Oncology profile →
Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children's Oncology Group

2012 482 citations Richard B. Womer, Daniel C. West et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Mark Krailo

Since Specialization

Citations

This map shows the geographic impact of Mark Krailo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Krailo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Krailo more than expected).

Fields of papers citing papers by Mark Krailo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Krailo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Krailo. The network helps show where Mark Krailo may publish in the future.

Co-authorship network of co-authors of Mark Krailo

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Krailo. A scholar is included among the top collaborators of Mark Krailo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Krailo. Mark Krailo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Validation of the stratification for newly diagnosed hepatoblastoma: An analysis from the Children’s Hepatic tumors International Collaboration (CHIC) database 2024 ·SHILAP Revista de lepidopterología ·Arun Rangaswami, Angela D. Trobaugh‐Lotrario, Rudolf Maibach, Allison F. O’Neill, Daniël C. Aronson, Rebecka L. Meyers, Mark Krailo, Jin Piao, Eiso Hiyama, Tomoro Hishiki, Marc Ansari, (unknown), Piotr Czauderna, Marcio H. Malogolowkin, Beate Häberle	0
2	Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031 2023 ·Journal of Clinical Oncology ·Thomas F. Cash, Mark Krailo, Allen Buxton, Bruce Pawel, John H. Healey, Odion Binitie, Karen J. Marcus, Holcombe E. Grier, Patrick J. Grohar, Damon R. Reed, Aaron R. Weiss, Richard Görlick, Katherine A. Janeway, Steven G. DuBois, Richard B. Womer	6
3	Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group 2022 ·European Journal of Cancer ·Pooja Hingorani, Mark Krailo, Allen Buxton, Paul R. Hutson, Paul M. Sondel, Mitchell B. Diccianni, Alice L. Yu, Carol D. Morris, Richard B. Womer, Brian D. Crompton, R. Lor Randall, Lisa A. Teot, Steven G. DuBois, Katherine A. Janeway, Richard Görlick, Michael S. Isakoff	23
4	Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol 2021 ·Journal of Clinical Oncology ·Carlos Rodríguez‐Galindo, Mark Krailo, Emília M. Pinto, Farzana Pashankar, Christopher B. Weldon, Li Huang, Eliana Maria Monteiro Caran, John Hicks, M. Beth McCarville, David Malkin, Jonathan D. Wasserman, (unknown), Michael P. LaQuaglia, Deborah Ward, Gerard P. Zambetti, Maria José Mastellaro, Alberto S. Pappo, Raul C. Ribeiro	47
5	Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group 2021 ·Pediatric Blood & Cancer ·Anderson B. Collier, Mark Krailo, Ha Dang, Steven G. DuBois, Douglas S. Hawkins, Mark L. Bernstein, Lisa Bomgaars, Damon R. Reed, Richard Görlick, Katherine A. Janeway	13
6	A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921) 2019 ·Clinical Cancer Research ·Yaël P. Mossé, Elizabeth Fox, David T. Teachey, Joel M. Reid, Stephanie L. Safgren, Hernán Carol, Richard B. Lock, Peter J. Houghton, Malcolm A. Smith, David Hall, Donald A. Barkauskas, Mark Krailo, Stephan D. Voss, Stacey L. Berg, Susan M. Blaney, Brenda J. Weigel	79
7	Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group 2018 ·Journal of Clinical Oncology ·Adriana Fonseca, Caihong Xia, Armando J. Lorenzo, Mark Krailo, Thomas A. Olson, Farzana Pashankar, Marcio H. Malogolowkin, James F. Amatruda, Deborah F. Billmire, Carlos Rodríguez‐Galindo, A. Lindsay Frazier, Furqan Shaikh	9
8	Prevention of cisplatin‐induced hearing loss in children: Informing the design of future clinical trials 2018 ·Cancer Medicine ·Lori M. Minasian, A. Lindsay Frazier, Lillian Sung, Ann M. O’Mara, Joseph Kelaghan, Kay W. Chang, Mark Krailo, Brad H. Pollock, Gregory H. Reaman, David R. Freyer	15
9	Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group 2016 ·Clinical Cancer Research ·Kieuhoa T. Vo, (unknown), C. Lorrie Epling, Elizabeth Sinclair, Douglas S. Hawkins, Holcombe E. Grier, Katherine A. Janeway, Phillip Barnette, (unknown), Mark Krailo, Donald A. Barkauskas, Katherine K. Matthay, Richard B. Womer, Richard Görlick, Stephen L. Lessnick, Crystal L. Mackall, Steven G. DuBois	17
10	p27 Is a Candidate Prognostic Biomarker and Metastatic Promoter in Osteosarcoma 2016 ·Cancer Research ·Yiting Li, Manjula Nakka, (unknown), Ching C. Lau, Mark Krailo, Donald A. Barkauskas, John M. Hicks, Tsz‐Kwong Man	29
11	Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children's Oncology Group breakdown → 2012 ·Journal of Clinical Oncology ·Richard B. Womer, Daniel C. West, Mark Krailo, Paul S. Dickman, Bruce Pawel, Holcombe E. Grier, Karen J. Marcus, Scott L. Sailer, John H. Healey, John P. Dormans, Aaron R. Weiss	482
12	Complete Surgical Resection Is Curative for Children With Hepatoblastoma With Pure Fetal Histology: A Report From the Children's Oncology Group 2011 ·Journal of Clinical Oncology ·Marcio H. Malogolowkin, Howard M. Katzenstein, Rebecka L. Meyers, Mark Krailo, Jon M. Rowland, Joel E. Haas, Milton J. Finegold	110
13	Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group 2011 ·Journal of Clinical Oncology ·Suman Malempati, Brenda J. Weigel, Ashish M. Ingle, Charlotte H. Ahern, Julie M. Carroll, Charles T. Roberts, Joel M. Reid, Stephen C. Schmechel, Stephan D. Voss, (unknown), Helen X. Chen, Mark Krailo, Peter C. Adamson, Susan M. Blaney	147
14	Current Treatment Protocols Have Eliminated the Prognostic Advantage of Type 1 Fusions in Ewing Sarcoma: A Report From the Children's Oncology Group 2010 ·Journal of Clinical Oncology ·(unknown), Lingyun Ji, (unknown), Hiroyuki Shimada, Michele R. Wing, Mark Krailo, Stephen L. Lessnick, Neyssa Marina, Timothy J. Triche, Richard Sposto, Richard B. Womer, Elizabeth R. Lawlor	95
15	Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study 2009 ·Journal of Clinical Oncology ·Linda Granowetter, Richard B. Womer, Meenakshi Devidas, Mark Krailo, Chenguang Wang, Mark L. Bernstein, Neyssa Marina, Patrick J. Leavey, Mark C. Gebhardt, John H. Healey, Robert C. Shamberger, Allen M. Goorin, James S. Miser, James S. Meyer, Carola A.S. Arndt, Scott L. Sailer, Karen J. Marcus, Elizabeth J. Perlman, Paul S. Dickman, Holcombe E. Grier	235
16	Redefining the Role of Doxorubicin for the Treatment of Children With Hepatoblastoma 2008 ·Journal of Clinical Oncology ·Marcio H. Malogolowkin, Howard M. Katzenstein, Mark Krailo, Zhengjia Chen, John J. Quinn, Marleta Reynolds, Jorge A. Ortega	45
17	Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group breakdown → 2008 ·Journal of Clinical Oncology ·Paul A. Meyers, Cindy L. Schwartz, Mark Krailo, John H. Healey, Mark L. Bernstein, Donna L. Betcher, William S. Ferguson, Mark C. Gebhardt, Allen M. Goorin, Michael B. Harris, Eugenie S. Kleinerman, Michael P. Link, Helen Nadel, Michael L. Nieder, Gene P. Siegal, Michael A. Weiner, Robert J. Wells, Richard B. Womer, Holcombe E. Grier	520
18	Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group 2007 ·Blood ·Hisaki Fujii, Geoff D.E. Cuvelier, Kevin She, (unknown), Hiromi Shimizu, Amina Kariminia, Mark Krailo, Zhengjia Chen, (unknown), (unknown), Frederick D. Goldman, Stephen Grupp, Donna A. Wall, Andrew L. Gilman, Kirk R. Schultz	104
19	Local Control in Pelvic Ewing Sarcoma: Analysis From INT-0091—A Report From the Children's Oncology Group 2006 ·Journal of Clinical Oncology ·Torunn I. Yock, Mark Krailo, Christopher Fryer, Sarah S. Donaldson, James S. Miser, Zhengjia Chen, Mark L. Bernstein, Fran Laurie, Mark C. Gebhardt, Holcombe E. Grier, Nancy J. Tarbell	100
20	Prognostic implications of blast cell morphology in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. 1985 ·PubMed ·Miller Dr, Mark Krailo, Bleyer Wa, (unknown), (unknown), (unknown), Jennifer Weiner, D Hammond	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact